PT  - JOURNAL ARTICLE
AU  - Bogdana Basina
AU  - Tetyana Pertseva
AU  - Lyudmyla Konopkina
AU  - Vitalii Berezovskyi
AU  - Juliya Gordienko
TI  - Are there serum levels of MMP-2 and MMP-9 may be markers of COPD phenotypes?
DP  - 2012 Sep 01
TA  - European Respiratory Journal
PG  - P3474
VI  - 40
IP  - Suppl 56
4099  - http://erj.ersjournals.com/content/40/Suppl_56/P3474.short
4100  - http://erj.ersjournals.com/content/40/Suppl_56/P3474.full
SO  - Eur Respir J2012 Sep 01; 40
AB  - Aim: to optimize an anti-inflammatory therapy in COPD patients (pts).Materials and methods. 24 pts in stable phase (age – 63.5 ± 3,9 yrs), divided into the subgroups according to the stage of COPD. Measurements included clinical status, spirometry, serum levels of MMP-2 and MMP-9 by immune-fluorescent method (in conventional units).Results. Level of MMP-2 in all COPD pts was lower than in control (Table 1), besides it correlated with FEV1 (r=-0.47, p=0.02). Level of MMP-9 in COPD pts in the whole was significantly higher than in control; but regardless of FEV1 there were selected two phenotypes of COPD: 1st– with normal level of MMP-9, 2nd – with high one (Table 2).View this table:table 1View this table:table 2Conclusion: 1) low level of MMP-2 in all COPD pts reflects delay of tissues regeneration and intensification of inflammation because of degradation of monocyte chemotactive protein-3 even starting with II st.; 2) high level of MMP-9 in some COPD pts reflects degradation of collagen, remodulation of tissues and intensification of inflammation; 3) MMP-9 may be used as a marker of COPD phenotypes and thus – to optimize an anti-inflammatory therapy.